TANDVARDS-OCH LAKEMEDELSFORMANSVERKET

Their core work

TLV (Tandvårds- och läkemedelsförmånsverket) is Sweden's Dental and Pharmaceutical Benefits Agency — the public authority that decides which medicines and dental treatments are subsidized by the Swedish state. Their core work involves health technology assessment (HTA), pricing decisions, and cost-effectiveness analysis of pharmaceuticals and medical devices. In H2020 projects, they contribute real-world regulatory and reimbursement expertise, helping develop better methods for evaluating health technologies, incorporating patient preferences, and using real-world data in coverage decisions.

What they specialise in

How they've shifted over time

TLV's H2020 involvement shows a clear deepening of HTA methodology over a short but focused 2017–2024 window. Their first project (DO-IT, 2017) focused broadly on big data for health outcomes, while later projects progressively narrowed toward actionable HTA tools (IMPACT HTA, 2018) and next-generation assessment methods incorporating personalized treatment and EUnetHTA alignment (HTx, 2019). The trajectory moves from general data-driven policy toward highly specific, patient-centred HTA methodologies suited for regulatory implementation.

TLV is moving toward patient-centred, real-world-data-driven HTA frameworks aligned with EUnetHTA, positioning them as a key partner for any project needing regulatory-grade health technology evaluation.

How they like to work

TLV participates exclusively as a consortium partner, never as coordinator — consistent with their role as a national regulatory agency contributing domain authority rather than managing research projects. With 61 unique partners across 18 countries from just 3 projects, they operate in large, pan-European consortia typical of HTA harmonization initiatives. Their value to a consortium is institutional: they bring the perspective of an actual decision-making body, not just academic analysis.

Despite only 3 projects, TLV has built connections with 61 partners across 18 countries — reflecting their participation in major pan-European HTA consortia that bring together regulatory agencies, universities, and health systems from across the continent.

What sets them apart

TLV is not a research organization — it is the actual Swedish authority that makes binding reimbursement decisions on medicines. This gives them a rare position in EU research: they are an end-user of HTA research, not just a producer of it. For consortium builders, TLV offers direct regulatory relevance and a pathway from research methods to real policy implementation in one of Europe's most respected healthcare systems.

Highlights from their portfolio

• HTx
  Largest project by funding (EUR 301,852) and longest duration (2019–2024), focused on next-generation HTA to support personalized, real-time health technology assessment across Europe.
• IMPACT HTA
  Covers the broadest methodological scope — from costing and value assessment to patient preferences and orphan drugs — directly feeding into TLV's regulatory decision-making process.